Sentences with phrase «for pharmacogenomic»

Recently, the DruGeVar database was included as a plug - in module for the pharmacogenomic biomarkers module of FINDbase database, while new data visualization functionalities were added to facilitate data querying output.

Members of the Genome Informatics Working Group have recognized the need to provide a comprehensive resource for pharmacogenomic biomarkers information for those drugs that are approved by regulatory authorities.

This project indicated that not only a vast number of novel potentially functional variants in a total of 231 pharmacogenes was identified but also demonstrated the value of whole - genome sequencing for pharmacogenomic testing by capturing over 18,000 variants per individual in these pharmacogenes.

With a potential universe of nearly two and a half million people (including employees and their families), the opportunity for pharmacogenomic and clinical research is immense.

The fourth part of this course provides an outline of databases and other useful resources for Pharmacogenomics, such as the PharmGKB knowledgebase, etc..

He is the first Associate Director for Oncology Research in the Institute for Pharmacogenomics and Individualized Therapy.

He is the Associate Editor for Pharmacogenomics.

Not exact matches

«Precision medicine is already positively affecting providers (for example, by reducing ED visits by 30 % through application of molecular profiling treatment strategy); payers ($ 25 billion expected annual spending on genetic tests by 2021, and 45 % of FDA approvals were geared toward targeted therapies in 2013); and pharma (the pharmacogenomics market is expected to be $ 7.5 billion by 2017).»

Pharmacogenomics — Personalized Drugs, Personalized Careers Even in one of the worst years ever for employment in the biotech industry, according to Jim Kling, pharmacogenomics trainees find themselves with abundanPharmacogenomics — Personalized Drugs, Personalized Careers Even in one of the worst years ever for employment in the biotech industry, according to Jim Kling, pharmacogenomics trainees find themselves with abundanpharmacogenomics trainees find themselves with abundant opportunities.

Kling describes the emerging pharmacogenomics field and the promise it holds for scientists.

For aspiring geneticists, the lesson of the two companies» transformations is that genetics is moving into the realm of the practical, with the promise of personalized medicine and pharmacogenomics.

Such collaboration makes sense to Michael Phillips, scientific director of Genome Quebec Pharmacogenomics Centre and the Montreal Heart Institute, who has worked for both industry giants and universities.

«What most pharma look to me for is my 10 years of experience in pharmacogenomic clinical drug trial design and result interpretation,» he explains.

One current study looks at the pharmacogenomic profile of asthma patients and healthy controls, and these data will serve as a reference database for future studies.

Furthermore, results of this study provide essential directions to future pharmacogenomic research for reduction of ADR - related hospitalizations in Singapore,» said Professor Alexandre Chan, co-senior author of the British Journal of Clinical Pharmacology study.

And the field of pharmacogenomics, which was new when the research network began in 2000, has matured enough for its scientists to compete effectively with grant applicants in other fields, says Lorsch.

A recent study of a new course in pharmacogenomics at Washington State University Spokane found the class expanded students» understanding of these possibilities for their profession.

His research interests involve pharmacogenomics for hemoglobinopathies and neuropsychiatric disorders, transcriptional regulation of human fetal globin genes and genotype - phenotype correlation in human genetic disorders.

A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics.

A pharmacogenomic method for individualized prediction of drug sensitivity.

Although pharmacogenomics has great potential for clinical utility when used accordingly, many third party payers, including Medicare, may only cover testing for certain disease diagnoses and usually after therapy failure.

Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost - effective and results in a better outcome for patients.

University of Arkansas for Medical Sciences Advancing regulatory science through translational pharmacogenomics

An online resource triangulating drugs with genes and biomarkers for clinical pharmacogenomics.

In furtherance of their mutual interest in improving fundamental and clinical pharmacogenomics and its translation into clinical practice, the two organizations have agreed: (a) cooperate and collaborate on programs and activities of mutual interest, (b) work together to provide education symposia / workshops in developing countries and regions, and (c) foster collaborative research to better understand the genetic basis for ethnic diversity in the response to and adverse effects from medicines.

deCODE plans to use its pharmacogenomic work to develop and market a test that can be used to target the prescription of glucocorticoids to those patients for whom these compounds provide the most effective relief with the least possible side - effects.

This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.

deCODE's pharmacogenomic research is particularly vital in the near term because glucocorticoids, which represent one of the most widely - used and powerful treatments for asthma, can also have severe side - effects, particularly in children.

15:00 15:30 Surakameth Mahasirimongkol, Medical Researcher, National Institute of Health, Department of Medical Sciences, Ministry of Public Health and Scientific manager, Pharmacogenomic research project, Thailand Center For Excellence in Life Sciences (TCELS)

Pharmacogenomics: Pharmacogenomics is the study of how a person's genetic makeup affects how medications and medication doses are likely to work best for a particular person or which individuals are more likely to suffer adverse consequences.

«We are pleased to be applying our expertise in in vitro pharmacogenomics to assist Wyeth in the development of new treatment for respiratory disease,» said Dr. Kari Stefansson, CEO of deCODE.

deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease

deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease Reykjavik, ICELAND, November 20, 2002 — deCODE genetics (Nasdaq / Nasdaq Europe: DCGN) today announced the...

Whole - genome sequencing, chromosomal microarray analysis, and pharmacogenomics present new ethical questions and dilemmas for physicians to consider.

For example, it is used to identify correlations between gene sequences and diseases, to predict protein structures from amino acid sequences, to aid in the design of novel drugs, and to tailor treatments to individual patients based on their DNA sequences (pharmacogenomics).

The 2nd session provided an overview of cases, as evidence for clinical use of pharmacogenomics, focusing onTPMT genotyping for thiopurine treatment (Dr. Marieke Coenen, Radboud University, Nijmegen, the Netherlands), DPYD genotyping (Dr. Linda Henricks, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands), tamoxifen and CYP2D6 genotyping (Prof. Matthias Schwabb, Margarete Fisher Bosch Institute, Stuttgart, Germany) and SLCO1B1 and statin pharmacogenomics (Prof. Mikko Niemi, University of Helsinki, Helsinki, Finland).

They found that seven of these frequently prescribed medications warranted pharmacogenomic guidelines for clinical consideration.

Proponents of personalized medicine were thankful for several developments that show this trend is picking up speed: CVS followed Medco's example in expanding pharmacogenomic testing, while biotech and pharma companies, as well as the National Cancer Institute, stepped up their investment in the field.